Pushing the Boundaries of Drug Development: Is Lipinski’s Rule of Five Still Relevant?

Dave Miller, Ph.D., CSO of AustinPx, challenges the continued relevance of Lipinski’s Rule of Five (Ro5) in today’s pharmaceutical landscape. As technologies like AI and in-silico modeling reshape drug discovery, modern compounds often deviate from Ro5 guidelines yet demonstrate significant therapeutic potential. However, these nonconforming molecules can face hurdles in development due to solubility and scalability issues. KinetiSol Technology, AustinPx’s advanced amorphous dispersion platform, offers a proven solution by enabling exceptional bioavailability and efficient manufacturing processes. By integrating KinetiSol early in development, AustinPx not only ensures these innovative candidates are optimized for clinical and commercial success but also redefines how the industry approaches drug development challenges.